Detection of Fecal DNA Methylation for Colorectal Neoplasia : Does It Lead to an Optimal Screening Test? by Nagasaka, Takeshi et al.
Acta Medica Okayama
Volume 60, Issue 5 2006 Article 1
OCTOBER 2006
Detection of Fecal DNA Methylation for
Colorectal Neoplasia : Does It Lead to an
Optimal Screening Test?
Takeshi Nagasaka∗ Ajay Goel†
Nagahide Matsubara‡ Noriaki Tanaka∗∗
∗Okayama University,
†Baylor University Medical Center,
‡Okayama University,
∗∗Okayama University,
Copyright c©1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.
Detection of Fecal DNA Methylation for
Colorectal Neoplasia : Does It Lead to an
Optimal Screening Test?∗
Takeshi Nagasaka, Ajay Goel, Nagahide Matsubara, and Noriaki Tanaka
Abstract
Aberrant promoter methylation, an ‘epigenetic’ form of genomic instability that leads to tran-
scriptional silencing of tumor suppressor genes, is increasingly being recognized as a crucial com-
ponent in the evolution of human cancers. With our limited knowledge of the molecular basis
and timing of the initiation of altered methylation events in the stepwise progression of cancers,
the biggest challenge we currently face is to identify novel biomarkers and technologies for the
timely screening of patients carrying such alterations. One such strategy would be to develop tests
for the detection of fecal DNA methylation patterns that will improve the sensitivity of noninva-
sive screening tests for colorectal neoplasia, and moreover, will decrease both mortality and the
incremental costs of treating colorectal cancers.
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promising noninvasive screening tool for vari-
ous human malignancies including colorectal 
neoplasia is to assay for molecular biomarkers that 
represent a ‘speciﬁ c’ or ‘spectrum’ of genetic and/or 
epigenetic alterations.  In this context,  fecal DNA 
testing based on genetic alterations has been an area 
of active investigation since 1992,  and has gradually 
evolved into the development of multi-target DNA 
assays [1,  2].  Despite the enthusiasm in this 
approach for investigating genetic mutational signa-
tures,  up till now there have only been 2 large-scale 
studies that have reported data on fecal-based testing 
[3].  The successful extrapolation of such a strategy 
is extremely complex and diﬃ  cult to achieve due to 
the challenges it poses to fecal DNA testing based 
upon the detection of epigenetic alterations,  such as 
DNA methylation [4,  5].  Nonetheless,  the interest 
in this ﬁ eld is immense,  and the past several years 
have seen an explosion in investigations dealing with 
the identiﬁ cation of epigenetic markers in cancer [6ﾝ
8].  To reap the full potential of this methodology, 
investigators have based their assays on the unique 
diﬀ erences in methylation patterns between the ‘can-
cerous’- and ‘normal’-appearing tissues,  diﬀ erences 
that form the basis for the development of noninva-
sive biomarkers to detect the presence of tumors in 
blood,  sputum,  urine,  and stool samples [5,  9].  To 
test the validity and usefulness of fecal-based epigen-
etic marker screening,  human colorectal cancer has 
provided a good model for investigating whether 
DNA methylation can be adopted as an optimal diag-
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nostic screening test,  since several other noninvasive 
screening tools including fecal occult blood testing 
(FOBT) and fecal DNA testing based on genetic 
alterations are currently the subjects of active 
research.
　　However,  in contrast to the relatively well 
accepted mutation-based fecal DNA testing [1ﾝ3], 
methylation-based testing has been initiated more 
recently,  and is beginning to identify adequate spe-
ciﬁ c markers that are representative of epigenetic 
‘signature’ alterations.  All of these investigations 
will be useful,  as in the long run,  the challenges to 
discovering new speciﬁ c markers and technologies 
will not only improve noninvasive screening tests, 
but will also help reduce both overall patient mortal-
ity and the incremental costs of treating colorectal 
neoplasia.
Fecal Occult Blood Testing (FOBT) 
and Colonoscopies
　　Human colorectal cancer has emerged as an exper-
imental model for the introduction of innovative and 
eﬀ ective cancer screening and early detection tools 
in large populations because advanced malignant 
tumors in the colon are accompanied by a signiﬁ -
cantly high rate of mortality.  The problem is further 
compounded when weighed in economic terms,  as the 
longer persistent treatment that is necessary when 
there is a failure to diagnose these lesions early 
leads to substantive incremental treatment costs. 
FOBT can reduce colorectal cancer mortality by 15
ｵﾝ33ｵ through the early detection and removal of 
adenomatous polyps and cancers by colonoscopies or 
surgical operations [10ﾝ15].  Even though FOBT 
has a speciﬁ city of 95ｵ,  the usefulness of FOBT is 
somewhat limited due to its lack of sensitivity,  which 
only ranges somewhere between 15ﾝ30ｵ [16],  espe-
cially for advanced adenomas [17,  18].  Similarly, 
even though colonoscopy has a sensitivity of over 90ｵ, 
and ﾝ99ｵ speciﬁ city for the detection of adenocarci-
noma and advanced adenomas,  this procedure suﬀ ers 
from the practical limitation that it requires bowel 
preparation and sedation,  which causes patient dis-
comfort and a small risk of serious medical complica-
tions [16,  19ﾝ23].  An optimal screening test is 
deﬁ ned as one that is easy to conduct,  noninvasive, 
less expensive,  and acceptable to the larger popula-
tion [24].  Thus,  the challenge is to tailor a non-
invasive screening strategy that could be employed 
for the detection of colorectal neoplasia in its early 
stages,  thus eliminating the need for other expensive 
and invasive surgical procedures.
Fecal DNA Testing Based on 
Genetic Alterations
　　Since it was concluded that no single ‘speciﬁ c’ 
gene mutation can be identiﬁ ed and universally attrib-
uted to all colorectal cancers,  it became necessary to 
use larger panels of markers targeted for certain 
mutations to identify a speciﬁ c human malignancy [2, 
3,  25].  One example of such multi-target DNA test-
ing is the strategy that can detect up to 21 speciﬁ c 
mutations in the adenomatosis polyposis coli (APC), p53, 
K-ras gene,  together with a microsatellite instability 
marker (BAT-26),  and long-fragment DNA.  Most 
reports using this assay have been based on an 
approach developed either by EXACT Sciences 
(Maynard,  MA,  USA) or using the commercially 
available PreGen-Plus (Lab Corp,  Burlington,  NC, 
USA) test.  However,  these assays require a large 
volume of fecal sample from which puriﬁ ed DNA is 
prepared using oligonucleotide-based hybrid capture 
[3].  An initial small number of pilot studies reported 
that this approach had a sensitivity that varied from 
62ﾝ91ｵ for cancer detection,  and 27ﾝ82ｵ for ade-
nomatous polyps,  with a high degree of speciﬁ city 
for subjects without colorectal neoplasia ranging 
from 93ﾝ98ｵ [2,  25ﾝ27].  Similarly,  a subsequent 
larger multi-center study (evaluating 4,404 subjects) 
using this panel reported a sensitivity of 52ｵ for 
invasive cancers and 18ｵ for advanced neoplasms, 
with a speciﬁ city of 94ｵ for subjects with negative 
ﬁ ndings on colonoscopy (Table 1) [3].
Fecal DNA Testing Based on 
Epi-genetic Alterations
　　More recently,  there has been growing interest in 
extending this methodology to another possible DNA-
based target,  i.e.,  the detection of aberrant DNA 
hypermethylation of CpG islands in the genes [4,  5, 
28].  Epigenetic alterations are deﬁ ned as heritable 
signatures of information other than nucleotide 
sequences.  In mammals,  almost all 5-methylcytosine 
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(m5C) sequences occur in the 5’-CpG-3’ dinucleotide 
sequences that appear at a relatively low frequency 
in the genome [29].  Nevertheless,  several clusters 
of CpG sites are present in the genome,  and these 
clusters of CpG sites are deﬁ ned as CpG islands [30]. 
CpG islands are typically unmethylated under normal 
conditions,  except for the imprinted regions of one 
parent allele and inactive X chromosome [31ﾝ33].  In 
cancerous cells,  CpG islands within gene promoters 
are recognized as crucial components of cancer initia-
tion and progression because tumor-suppressor genes, 
such as CDKN2A and BRCA1,  are inactivated by 
hypermethylation in their promoter CpG islands [34]. 
Methylation analysis of a number of gene promoters 
in DNA from stool samples has been less comprehen-
sively investigated,  but has been suggested to be a 
sensitive diagnostic tool for colorectal tumors [35ﾝ
40].  Table 2 shows summarized data from all the 
reports to date on fecal DNA testing targeted for 
epigenetic alterations.  The pilot studies reporting 
fecal DNA testing on epi-genetic alterations had a 
sensitivity varying from 42ｵ to 77ｵ for cancer, 
and 31ｵ to 55ｵ for adenomas,  and an overall speci-
ﬁ city ranging from 63ｵ to 100ｵ for subjects with-
out colorectal neoplasia.  Compared with multi-target 
DNA testing,  fecal DNA methylation testing has tra-
ditionally exhibited slightly lower sensitivity and 
speciﬁ city.  However,  the majority of these pilot 
studies were limited to analysis of a single epi-
genetic biomarker analogous to fecal DNA testing of 
a speciﬁ c genetic alteration.  Such an approach is 
inherently ﬂ awed,  because unlike genetic alterations, 
which can be more precise and may involve a speciﬁ c 
gene/loci,  the biological signiﬁ cance of methylation 
changes is probably greater when they are evaluated 
using the multiple biomarkers that are required to 
enhance the overall sensitivity and speciﬁ city of 
these assays.  This use of multiple biomarkers is 
especially important because several genes are fre-
quently methylated in both colorectal cancers and 
premalignant adenomas relative to the lower fre-
quency of methylation that can be detected in their 
counterpart normal-appearing mucosa [41ﾝ43].  This 
might be one of the reasons for the observed 
decreased speciﬁ city of fecal DNA methylation test-
ing in comparison to conventional tests that involve 
the evaluation of a speciﬁ c ‘genetic’ alteration. 
Despite the fact that normal mucosa displays some 
degree of methylation,  there is still a signiﬁ cant 
opportunity to design an assay that can distinguish 
patients with neoplasia from those without neoplasia 
using a selected panel of genes that have a consider-
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Table 1　　Colorectal Neoplasia Detection by Multi-target DNA 
Testing PreGen-Plus in Stool
Reference
Sensitivity,  % (n) Speciﬁ city＊,  
% (n)Cancer Adenoma
Ahlquist et al. [2] 91 (20/22) 82 ( 9/11) 　 93 (26/28) 　　
Tagore et al. [25] 63 (33/52) 57 (16/28) 　 98.2 (111/113)　
Brand et al. [26] 69 (11/16) ﾝ ﾝ
Calistri et al. [27] 62 (33/53) ﾝ 97 (37/38) 　　
Imperiale et al. [3] 52 (16/31) 18.2 (76/418)  94.4 (1344/1423)
＊Speciﬁ city for subjects without colorectal neoplasia.
Table 2　　Colorectal Neoplasia Detection by Fecal DNA Testing based on Epigenetic alterations in Stool
Reference Biomarker
Sensitivity,  % (n) Speciﬁ city＊,  
% (n) MethodCancer Adenoma
Chen et al. [40] Vimentin 46 (43/94) ﾝ 90 (178/198) MSP
Muller et al. [35] SFRP2 77 (10/13) ﾝ 77 (10/13)　 Methylight
Lenhard et al. [39] HIC1 42 (11/26) 31 ( 4/13) 100 (32/32) 　 MSP
Petco et al. [38] CDKN2A & MGMT ﾝ 55 (16/29) 63 (12/19)　 MSP
CDKN2A ﾝ 31 ( 9/29) 84 (16/19)　
MGMT ﾝ 48 (14/29) 72 (13/18)　
hMLH1 ﾝ  0 ( 0/29) 90 (17/19)　
＊Speciﬁ city for subjects without colorectal neoplasia.
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able diﬀ erence in the degree and frequency of meth-
ylation.
Seeking Tumor-speciﬁ c ‘Hot Spots (/markers/
biomarkers)’ of Aberrant Methylation
　　Aberrant DNA methylation is often mistakenly 
considered to be uniformly spread around the core 
region of the promoter with a CpG island.  In reality, 
however,  the methylation pattern is not homogeneous 
among various CpG sites within a CpG island.  For 
instance,  the hMLH1 gene,  which is one of the major 
DNA mismatch repair genes,  has a large CpG island 
within its promoter that clearly divides it into at 
least 2 discrete regions of methylation (Fig.  1). 
Deng et al. examined the methylation status of 3 
regions (A,  B and C) in the hMLH1 promoter,  and 
compared the methylation status to the gene expres-
sion in 24 cell lines [44].  They concluded that only 
the C region was associated with the loss of gene 
expression,  an observation that was later conﬁ rmed 
by a large cohort of clinical colorectal cancer cases 
[45,  46].  In particular,  the methylation in regions 
A and B occurs in normal mucosa,  but the methyla-
tion in region C occurs only in tumor tissues and is 
considered to be “tumor-speciﬁ c” [46,  47].  This con-
cept added a new dimension to the interpretation of 
promoter hypermethylation data,  suggesting that the 
methylation of a ‘tumor-speciﬁ c’ region rather than 
the mere ‘presence’ of methylation is a key determi-
nant of the biological meaning of these ﬁ ndings.  This 
ﬁ nding arises another question : Even if the tumor-
speciﬁ c sites are selected as biomarkers for screen-
ing fecal DNA testing,  are these real tumor-speciﬁ c 
markers?
　　Belshaw et al. reported that,  using a nested meth-
ylation-speciﬁ c PCR (MSP) assay (Fig.  1),  virtually 
all DNA specimens,  irrespective of whether these 
were extracted from tumors,  normal mucosa,  or 
stool,  displayed frequent hypermethylation in ESR1, 
MGMT, HPP1,  CDKN2A,  APC and hMLH1 gene 
markers [36].  However,  this confusing scientiﬁ c 
scenario was rescued when a less sensitive semi-
quantitative assay,  a modiﬁ ed combined bisulﬁ te 
restriction analysis (COBRA),  was employed,  and all 
of these DNA samples were re-analyzed.  It was 
interesting that using such a methodology,  signiﬁ cant 
diﬀ erences in degrees of methylation in ESR1 and 
MGMT were detected between stool specimens and 
their counterpart normal mucosa specimens.  These 
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EPM2AIP1
hMLH1
C regionA and B region
MSP by Petko et al.
COBRA by Belshaw et al.
Nested MSP by Belshaw et al.
‘Tumor-speciﬁc’ methylated region 
The hMLH1 gene promoter region
Fig. 1　　Regions within the hMLH1 promoter.
In the hMLH1 promoter region,  the EPM2AIP1 gene is also located opposite of the hMLH1 gene.  Arrows indicate the transcriptional start 
site of both genes.  The non-coding region and coding region in exon1 are indicated by gray and black squares,  respectively.  The CpG 
site is shown by a vertical line.  Regions A,  B and C are deﬁ ned by Deng et al.  The regions A and B are methylated in normal colorectal 
mucosa,  and the methylation of this region is not aﬀ ected by the expression of the gene.  Region C is considered to include the ‘cancer-
speciﬁ c’ methylation sites.  The locations of MSP,  nested MSP,  and the COBRA assay used by fecal DNA testing are also shown in this 
Figure.
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diﬀ erences were previously not evident when using 
the traditional highly-sensitive MSP assay.  In this 
study,  the region of the hMLH1 promoter analyzed 
was also located within the C region (Fig.  1),  which 
is a “tumor -speciﬁ c” region.  All materials,  including 
stool specimens from patients with and without neo-
plasia,  displayed hypermethylation of hMLH1 when 
analyzed by nested-MSP but did not show hyper-
methylation when analyzed by the modiﬁ ed COBRA. 
On the other hand,  Petko et al.  [38] reported that, 
by using a traditional MSP,  the speciﬁ city of hMLH1 
assay was 90ｵ (Table 2),  and the analyzed region of 
hMLH1 promoter was similar to that of Belshaw et 
al. (Fig.  1).  The only conclusion that can be drawn 
regarding the observed diﬀ erences in the methylation 
status of the hMLH1 promoter C region between 
these pilot studies is that the diﬀ erences relate to 
the diﬀ erences in the sensitivity of the assays.
　　Both the MSP and COBRA methods use bisulﬁ te-
modiﬁ ed genomic DNA as a PCR ampliﬁ cation tem-
plate (Fig.  2) [48,  49].  Bisulﬁ te modiﬁ cation con-
verts cytosine to uracil at an eﬃ  ciency ｧ 99ｵ ; how-
ever,  the rate of conversion of methylated cytosine 
to uracil is very slow [50].  Thus,  bisulﬁ te-modiﬁ ed 
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A B
CGCG ACGT
TGTG ATGT
CGC
M allele 5’
U allele 5’
3’
3’
GCA
Methylation-Speciﬁc Primers
TGT ACA
Unmethylation-Speciﬁc Primers
1
U M
2
U M
3
U M
Methylation-speciﬁc PCR
(MSP)
Sample No.
CGCGM allele 5’
TGTGU allele 5’
Bst UI Site
Non-Speciﬁc Primers
1
100%0% 50%
2 3
3’
3’
Combined bisulﬁte restriction analysis
(COBRA)
Sample No.
Percentage of
Methylated allele
Fig. 2　　Schema of MSP and COBRA.
A : Methylation-speciﬁ c PCR (MSP).  Genomic DNA was chemically modiﬁ ed by sodium bisulﬁ te.  This modiﬁ cation generates a 
methylation-dependent sequence diﬀ erence at CpG sites by converting unmethylated cytosine residues to uracil when the CpG is not 
methylated,  while methylated cytosine residues are retained as cytosine when the CpG is methylated.  Methylation-speciﬁ c primers 
hybridize to the methylation-speciﬁ c sequence.  On the other hand,  unmethylation-speciﬁ c primers hybridize to the unmethylation-speciﬁ c 
sequence.  Thus one could detect methylation by the existence of PCR product.
B : Combined bisulﬁ te restriction analysis (COBRA).  The PCR primers for COBRA are designed to hybridize to the sequence with both 
methylated and unmethylated cytosines.  By use of a restriction enzyme that includes the CG sequence within its recognition sequence, 
one could anticipate the level of methylated allele in a quantitative manner.  Arrows indicate methylated alleles cut by BstUI (recognition 
sequence ; CGCG).
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DNA displays unique diﬀ erences between unmethyl-
ated cytosine and methylated cytosines,  which are 
subsequently used for the detection of methylated 
versus unmethylated alleles.  The MSP assay can 
detect as little as 0.1ｵ methylation,  while COBRA, 
being less sensitive,  can detect as few as 0.5ｵ meth-
ylated alleles.  The nested MSP is an even more 
highly sensitive assay,  and can detect a single meth-
ylated allele present in 50,000 unmethylated alleles 
(0.002ｵ) [51].  The pilot studies suggest that 0.002
ﾝ0.1ｵ of methylated DNA encoding the C region of 
hMLH1 promoter can be detected from the DNA 
extracted from exfoliated epithelial cells present in 
the total fecal mass.
　　In this context,  another interesting ﬁ nding was 
reported in the study by Chen et al.  [40],  who 
reported a dense CpG region located upstream of the 
ﬁ rst two-thirds of the ﬁ rst exon of vimentin gene, 
which is normally unmethylated,  but becomes methyl-
ated in colorectal cancers.  Interestingly,  the vimen-
tin gene is typically unmethylated and not expressed 
in normal colorectal epithelial crypt cells.  This 
would mean that the expression of this gene is not 
under epigenetic control.  In addition,  in order to 
identify the cancer-speciﬁ c ‘hot spots’ of DNA meth-
ylation sites within the vimentin gene promoter,  sev-
eral MSP primer sets were analyzed.  As anticipated, 
only 2 of these several sets of MSP primers were 
available for further screening.
　　At present,  only a small number of studies have 
been done on fecal DNA testing for investigating epi-
genetic alterations,  but still these initial pilot studies 
provide some clues and insight into the future design 
of newer technologies that will come into existence 
based upon the knowledge gained from these experi-
ments.  At least we have reached a certain degree of 
consensus on some of the previously less-understood 
paradigms ; ﬁ rst,  it has been clear that cancer-spe-
ciﬁ c methylation sites deﬁ nitely exist within gene 
promoters and could be used to distinguish patients 
with colorectal neoplasia from subjects without neo-
plasia,  even in a non-invasive test such as methyla-
tion detection in stool samples ; second,  the methyla-
tion status of CpG sites that do not inﬂ uence the 
associated gene expression can become the basis for 
developing new biomarkers for screening.  In reality, 
as many as half of such genes have CpG islands 
within their coding regions or introns [30],  a fact 
that distinguishes them from conventional tumor sup-
pressor genes,  which primarily have CpG sequences 
in the promoter regions only.
Conclusion
　　Thanks to the completion of the human genome 
project,  we can utilize information about the speciﬁ c 
arrangements of the conventional 4 nucleotide bases, 
adenine,  cytosine,  guanine and thymine.  However, 
additional information that aﬀ ects phenotypes is 
stored in the distribution of a modiﬁ ed base,  5-meth-
ylcytosine.  As of now,  our understanding of 5-meth-
ylcytosine is still in its infancy.  It is hoped that in 
the next few decades,  with the completion of the 
“epigenome” project,  we will acquire a better under-
standing of the distribution of 5-methylcytosine in 
various cell types,  including normal and neoplastic 
cells,  that will help improve future strategies for the 
early detection of cancers.  It goes without saying 
that the completion of such a project would provide 
seminal insights into the complexities of the methyla-
tion machinery that is believed to be an underlying 
‘epigenetic signature’ harbored in a large majority of 
human cancers.
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